Postoperative Mortality in Cancer Patients With Preexisting Diabetes

Systematic review and meta-analysis

OBJECTIVE — Diabetes appears to increase risk for some cancers, but the association between preexisting diabetes and postoperative mortality in cancer patients is less clear. Our objective was to systematically review postoperative mortality in cancer patients with and without preexisting diabetes and summarize results using meta-analysis.

RESEARCH DESIGN AND METHODS — We searched the Medical Literature Analysis and Retrieval System Online (MEDLINE) and Excerpta Medica Database (EMBASE) for articles published on or before 1 July 2009, including references of qualifying articles. We included English language investigations of short-term postoperative mortality after initial cancer treatment. Titles, abstracts, and articles were reviewed by at least two independent readers. Study population and design, results, and quality components were abstracted with standard protocols by one reviewer and checked for accuracy by additional reviewers.

RESULTS — Of 8,828 titles identified in our original search, 20 articles met inclusion criteria for qualitative systematic review. Of these, 15 reported sufficient information to be combined in meta-analysis. Preexisting diabetes was associated with increased odds of postoperative mortality across all cancer types (OR = 1.85 [95% CI 1.40–2.45]). The risk associated with preexisting diabetes was attenuated but remained significant when we restricted the meta-analysis to models that controlled for confounders (1.51 [1.13–2.02]) or when we accounted for publication bias using the trim and fill method (1.52 [1.13–2.04]).

CONCLUSIONS — Compared with their nondiabetic counterparts, cancer patients with preexisting diabetes are ~50% more likely to die after surgery. Future research should investigate physiologic pathways to mortality risk and determine whether improvements in perioperative diabetes care can reduce postoperative mortality.

Diabetes Care 33:931–939, 2010

Among cancer patients, preexisting diabetes is associated with a higher risk of all-cause long-term mortality (4). Because diabetes can lead to infections, metabolic derangements, and acute cardiovascular events, cancer patients with diabetes may also be at greater risk of short-term mortality, especially in the peri- and postoperative interval (2,5). However, this risk has not been systematically studied. We therefore sought to review and summarize data evaluating the risk of short-term postoperative mortality related to preexisting diabetes in newly diagnosed cancer patients.

RESEARCH DESIGN AND METHODS

Data sources and searches

We searched Medical Literature Analysis and Retrieval System Online (MEDLINE) and Excerpta Medica Database (EMBASE) from inception to 1 July 2009 for articles evaluating the effect of diabetes on any prognostic outcome in cancer patients. Our overall search strategy included terms for diabetes (e.g., diabetes, glucose intolerance, hyperglycemia), cancer (e.g., cancer, malignant neoplasm), and prognosis (e.g., mortality, survival, recurrence) and was limited to English language human studies. We also searched references of included articles.

Study selection

Our overall search targeted articles that met the following three criteria: 1) evaluated any prognostic outcome by glycemic status, 2) evaluated a cancer population, and 3) contained original data. The current review further required articles to evaluate short-term postoperative mortality after initial cancer surgery, including 30-day and hospital mortality. To be included in our meta-analysis, articles had to meet either of the following two criteria: 1) report a risk estimate (e.g., hazard ratio [HR], relative risk [RR], or odds ratio [OR]) relating preexisting diabetes to subsequent death and an estimate of precision such as a standard error or 95% CI or 2) report rates of short-term mortality in patients with and without diabetes as well as the prevalence of diabetes in the study population.

Data extraction and quality assessment

Titles, abstracts, and articles were reviewed independently by two authors. Disagreements were settled by consensus or a third review for adjudication. Ab
Cancer patients with preexisting diabetes

extracted data included study population characteristics, health outcomes (specifically short-term postoperative mortality for this report), adjustment variables, and study quality. Quality was assessed using elements of the STrengthening the Reporting of Observational studies in Epidemiology (STROBE) checklist for cohort studies that we considered important for quality in these studies (6). To judge quality, we abstracted information on population source; method of diabetes and outcome ascertainment; whether diabetes was the primary exposure variable or one of a group of prognostic variables; and adjustment for confounders.

Data synthesis and analyses
Articles reporting unadjusted or adjusted risk estimates (OR, RR, or HR) and confidence intervals (CIs) or standard errors (SEs) were included in the meta-analysis. An unadjusted OR was calculated for manuscripts reporting rates of mortality, study sample size, and prevalence of diabetes. SE of the OR was calculated using the delta method. If an article only reported multiple risk estimates by subgroup, these estimates were input separately into our meta-analysis. We attempted to contact four authors for additional unreported information necessary for inclusion in the meta-analysis, but none were able to furnish the required information. These four articles were only included in the systematic review.

The results of the overall systematic review are summarized qualitatively. Additionally, cancer sites with at least three studies meeting inclusion criteria are discussed in more detail. For the meta-analysis, potential sources of heterogeneity between studies were assessed using Cochran’s Q and I² statistics (7). Due to substantial between-study heterogeneity, we calculated a pooled OR including all estimates using the DerSimonian-Laird method for a random-effects model, which weights individual studies by the inverse of the variance (8). Publication bias was evaluated using Begg’s funnel plot and the Egger plot. Several sensitivity analyses were conducted. First, we excluded unadjusted risk estimates. We also calculated separate pooled estimates for population-based and clinical-based cohorts, as well as studies evaluating diabetes as the primary exposure or among prognostic factors. Next, we performed the Duval and Tweedie nonparametric trim and fill procedure to further assess the potential effect of publication bias. This method considers the possibility of hypothetical missing studies, imputes their ORs, and recalculates a pooled estimate (9). Finally, we evaluated the influence of each study on the overall estimate by calculating a random-effects pooled OR, omitting each estimate one at a time. We repeated the analysis of influence among studies with adjusted estimates. All analyses were conducted using STATA 10 (College Station, TX).

RESULTS

Search results
Our literature search yielded 8,828 articles, of which 20 were eligible for inclusion in the present systematic review of the risk of preexisting diabetes on short-term postoperative mortality in cancer patients after initial surgical treatment. Descriptive data and main results from these studies are presented according to cancer site (Table 1). Of these, 15 met additional inclusion criteria for our meta-analysis (Fig. 1).

Nineteen articles included in our systematic review evaluated postoperative, 30-day, or hospital mortality in cohorts of patients who had undergone cancer surgery; one article evaluated a composite outcome of hospital mortality or morbidity. Publication year ranged from 1983 to 2009. Studies evaluated the effect of preexisting diabetes in patients with colon or colorectal (n = 5) (10–14), esophageal and/or gastroesophageal junction (n = 5) (15–19), liver (n = 2) (20,21), lung (n = 4) (22–25), pancreatic (n = 2) (26,27), stomach (n = 1) (28), and prostate cancer (n = 1) (29). The studies were conducted in Europe (n = 8), the U.S. (n = 7), and Asia (n = 5). Sample sizes ranged from 70 to 32,621 with a median of 427. The prevalence of diabetes, where reported, ranged from 1 to 42% with a median of 10%. Crude postoperative mortality rates ranged from 0.73 to 53.5% with a median of 6.5%.

Quality varied across studies (see supplemental Table, available in an online appendix at http://care.diabetesjournals.org/cgi/content/full/dc09-1721/DC1). Five studies used population-based cohorts, and the other 15 used clinic-based cohorts. Two studies ascertained diabetes by a blood test, and the remainder used medical records (n = 18). A few studies used death registries (n = 3) to ascertain vital status, but most studies used medical records or study follow-up (n = 17). Only three studies focused specifically on diabetes; the remaining 17 studies investigated diabetes as one potential prognostic variable among many. Twelve studies reported unadjusted percentages or risk estimates of preexisting diabetes on short-term mortality, whereas the other eight reported adjusted estimates.

Systematic review
Of the 10 studies that reported simple percentages comparing cancer patients with and without preexisting diabetes, four reported that diabetes was associated with significantly higher short-term mortality, four reported nonsignificant differences, and two did not report a statistical comparison. Neither of the two studies reporting unadjusted estimates from regression models found a significant difference. Of the 10 adjusted estimates (eight studies) from regression models, five indicated significantly increased risk of postoperative mortality, one reported significantly increased risk of postoperative mortality or morbidity, and four found nonsignificant associations. No studies reported that diabetes was associated with significantly decreased short-term postoperative mortality.

Our search yielded at least three studies of colon/colorectal cancer, esophageal/gastrointestinal junction cancer, and lung cancer. Results from these studies are summarized below. We did not perform meta-analysis by cancer site because of insufficient number of studies with adjustment and the high degree of heterogeneity.

Five studies evaluated the risk of diabetes on postoperative mortality in colon (10,12) or colorectal (11,13,14) cancer. Koperna et al. (10) and Tsugawa et al. (12) both evaluated small clinical populations (n = 99 and n = 71, respectively) of patients >70 years of age undergoing emergency surgery for colon cancer. Both studies reported high rates of postoperative mortality (50.5 and 53.5%, respectively) and found a significant survival advantage for patients without diabetes in a simple comparison of postoperative mortality rates. Little et al. (11) and Jullumstro et al. (14) evaluated larger clinical cohorts (n = 727 and n = 1,194, respectively) of colorectal cancer patients and reported unadjusted rates of 30-day mortality in patients with and without diabetes. Little et al. (11) found that patients with diabetes had a significantly increased risk of 30-day mortality (8.2 vs. 2.4%, P = 0.02) in a cohort of patients with colorectal cancer that was metastatic to the liver and who underwent hepatic re-
| Author, year, country | Cancer site | Exclusion criteria | n with DM/n total (%) | Age (years) | Outcome (mortality rate) | Results | Adjustment variables |
|-----------------------|-------------|--------------------|-----------------------|-------------|-------------------------|--------|----------------------|
| Koperna et al., 1997, Austria (10) | Colon | No emergency surgery for colon cancer, aged ≤70 years, not treated between 1986 and 1995 | 11/99 (11%) | Mean ± SD 81.5 ± 5.9 | Postoperative mortality (50.5%) | DM: 91%; NG: 47% (P = 0.005) | None |
| Little et al., 2002, U.S. (11) | Colorectal | No hepatic resection, colorectal cancer not metastatic to the liver, not treated at Memorial Sloan-Kettering Cancer Hospital between 1990 and 1997 | 61/727 (8%) | Median (range) 62 (23–85) | 30-day mortality (2.9%) | DM: 8.0%; NG: 2.4% (P = 0.02) | None |
| Tsugawa et al., 2002, Japan (12) | Colon | No emergency surgery for colon cancer, aged ≤70 years, not treated between 1988 and 1997 | 10/71 (14%) | Mean ± SD 75.4 ± 5.1 | Postoperative mortality (53.5%) | DM: 80%; NG: 49% (P = 0.006) | None |
| Davila et al., 2005, U.S. (13) | Colorectal | No surgical resection of colorectal cancer within 6 months of diagnosis, previous colon cancer, ulcerative colitis, Crohn’s disease, not in Veteran’s Affairs database, not diagnosed between 1987 and 2000 | NA/32,621 | Mean ± SD 68 ± 9 | 30-day mortality (4.5%) | HR = 1.19 (1.04–1.36)* | Age, sex, race, marital status, metastatic disease, site, surgical volume, time of surgery |
| Jullumstrø et al., 2009, Norway (14) | Colorectal | Not histologically confirmed, not treated between 1980 and 2004 | 97/1,194 (8.1%) | DM: median 76.2; NG: median 71.7 | 30-day mortality (5.1%) | DM: 6%; NG: 5% (P = 0.61) | None |
| Zhang et al., 1994, Japan (15) | Esophagus | No esophagectomy (subtotal through right thoracotomy) between 1986 and 1989 | 42/100 (42%) | Mean (range) 60.7 (42–82) | Hospital complication mortality (7.0%) | OR = 1.19 (P = 0.024)8 | Age, ECG, operation, vital capacity, T-factor, creatinine clearance, 15’ indocyanine green test |
| Bartels et al., 1998, Germany (16) | Esophagus | No curative esophagectomy between 1982 and 1991 | NA/432 | Mean 56.7 | 30-day mortality (10.0%) | OR = NA (P > 0.05) | Karnofsky index, mental cooperation, vital capacity, arterial partial pressure of oxygen, aminopyrine breath test, cirrhosis, cardiac risk |
| Author, year, country | Cancer site | Exclusion criteria | n with DM/n total (%) | Age (years) | Outcome (mortality rate) | Results | Adjustment variables |
|-----------------------|-------------|-------------------|-----------------------|-------------|-------------------------|---------|----------------------|
| Karl et al., 2000, U.S. (17) | Gastroesophageal junction Esophagus or gastroesophageal junction | No esophagogastrectomy between 1989 and 1999 No esophagectomy, neoadjuvant chemotherapy, not treated between 1990 and 2003 | 15/143 (10%) | Mean (range) 63.7 (33–83) | 30-day mortality (2.1%) | DM: 13%; NG: 1% (P value NA) | None |
| Abunasra et al., 2005, U.K. (18) | Esophagus | No esophagectomy, neoadjuvant chemotherapy, not treated between 1990 and 2003 | 47/773 (6%) | Median 67.8 | 30-day mortality (3.5%) | DM: 11%; NG: 4% (P = 0.030) | None† |
| Wright et al., 2009, U.S. (19) | Esophagus | No esophagectomy, emergency operations, sites with inconsistent reporting, aged <30 years, missing data for age or discharge mortality, not treated between 2002 and 2007 | 373/2,315 (16%) | <60: 35%; 60–69: 35%; 70–80: 25%; 80+: 5% | Hospital mortality and morbidity (23.9%) | OR = 1.19‡ (P = 0.009) | Age, sex, race, comorbidities, Zubrod score, ASA class, steroids, induction therapy, smoking, BMI, time trend |
| Nagasue et al., 1993, Japan (20) | Liver | No radical hepatic resection between 1980 and 1986 | 66/229 (29%) | Mean (range) 60.8 (32–79) | Hospital mortality (10.5%) | DM: 15.2%; NG: 11.7% (P > 0.05) | None |
| Poon et al., 2002, Hong Kong (21) | Liver | No hepatic resection between 1989 and 1999 | 62/525 (12%) | Mean ± SD DM: 60.5 ± 9.7; NG: 52.4 ± 13.4 | 30-day mortality (3.0%) | DM: 3.2%; NG: 3.0% (P = 0.583) | None |
| Romano and Mark, 1992, U.S. (22) | Lung | No pneumonectomy, lobectomy, wedge or segmental resection; not adults; not discharged from non-federal acute care hospital; not principal or secondary diagnosis; not treated between 1983 and 1986 | 577/12,439 (5%) | Mean 64 | 30-day mortality (5.0%) | Lesser resections OR = 1.5 (1.1–2.2); Pneumonectomies OR = 1.4 (0.7–2.9) | Age, sex, primary diagnosis, resection type, comorbidities, type of hospital, hospital volume |
| Au et al., 1994, Scotland (23) | Lung | No pneumonectomy, aged <70 years, classified as medically unfit, not treated between 1980 and 1987 | 5/70 (7%) | Mean (range) 72.3 (70–82) | 30-day mortality (21.4%) | NA: Fisher’s exact test (P > 0.05) | None |
| Duque et al., 1997, Spain (24) | Lung | No thoracotomy between 1993 and 1994 | 46/605 (8%) | ≤70: 75%; >70: 25% | 30-day mortality (6.6%) | OR = 1.83 (0.68–4.91) | None† |
| Author, year, country | Cancer site | Exclusion criteria | n with DM/n total (%) | Age (years) | Outcome (mortality rate) | Results | Adjustment variables |
|-----------------------|------------|--------------------|-----------------------|-------------|-------------------------|---------|----------------------|
| Dominguez-Ventura et al., 2006, U.S. (25) | Lung | No pulmonary resection, aged <80 years, not non-small cell, not treated between 1985 and 2004 | 28/379 (7%) | Median (range) 82 (80–95) | 30-day mortality (6.3%) | OR = 0.71 (0.09–5.49) | None |
| Wu et al., 1995, Taiwan (26) | Stomach | No radical gastrectomy between 1987 and 1993 | 7/474 (1%) | NA | Hospital mortality (3.0%) | OR = NA* (P > 0.05) | Age, extent of gastric resection, combined organ resection, respiratory system disease |
| Andrén-Sandberg and Ihse, 1983, Sweden (27) | Pancreas | No total pancreatectomy, incomplete data, not treated between 1959 and 1982 | 12/86 (14%) | Mean 61.2 | Hospital mortality (29.1%) | DM: 58%; NG: 24% (P value NA) | None |
| Bakkevold and Kambestad, 1993, Norway (28) | Pancreas | No radical or palliative surgery for pancreatic cancer, unconfirmed adenocarcinoma of the exocrine pancreas or the papilla of Vater, not treated between 1984 and 1987 | NA/360 | Mean 67 | 30-day mortality (13.1%) | Radical pancreatectomy OR = NA (P > 0.05); Palliative surgery OR = 0.20 (0.06–0.64)¶ | Radical pancreatectomy: Karnofsky's index—palliative surgery: liver metastasis, Karnofsky's index |
| Wilt et al., 1999, U.S. (29) | Prostate | No radical prostatectomy at a Veterans Affairs Medical Center, not aged 45–84 years, not treated between 1986 and 1996 | 1,352/13,398 (10%) | Mean ± SD 65.0 ± 5.4 | 30-day mortality (0.73%) | OR = 1.87 (1.11–3.15) | Age, race, alcohol abuse, comorbidities, region |

ASA, American Society of Anesthesiology; DM, diabetes; NA, not available; NG, normoglycemic. *95% CI. †Study included multivariate model in which diabetes was not included. ‡Used hospital mortality plus morbidity as outcome. §Used four-level definition of diabetes based on oral glucose tolerance test results. ¶Diabetes population as reference.
Cancer patients with preexisting diabetes

Meta-analysis

Of the 20 studies with 22 risk estimates included in our systematic review, we excluded six estimates for the purpose of meta-analysis: four estimates for lack of sufficient information (16,23,26,28) and two for use of different exposure or outcome definitions from other included studies (15,19). Thus, we included in the meta-analysis 15 studies reporting 16 risk estimates.

Figure 2 displays the results of the meta-analysis of the 16 estimates in order of magnitude. Compared with their non-diabetic counterparts, cancer patients with preexisting diabetes had greater odds of mortality after surgery (OR 1.85 [1.40–2.45]). Although the studies included in the meta-analysis spanned different continents and cancer sites, the risk estimate was above the null in 15 of 16 estimates and significantly above the null in 9 of 16 estimates. This relationship was attenuated, but still statistically significant, after excluding unadjusted estimates (1.51 [1.13–2.02]; Table 2). Age (n = 4), sex (n = 4), and other comorbidities (n = 4) were adjustment variables in the majority of these studies (see Table 1 for a complete list in each study). The pooled risk estimates were lower in population-based cohorts (1.51 [1.13–2.02]) than clinic-based cohorts (2.28 [1.46–3.58]), likely because the former reported adjusted risk estimates and the latter did not. Estimates were similar in the three studies where diabetes was the primary exposure variable (1.69 [0.73–3.88]) and the 12 studies where diabetes was one of several prognostic variables (1.88 [1.38–2.55]). We observed evidence of publication bias according to the Begg test (P = 0.096) and the Egger plot (P = 0.011) (supplemental Fig. A). There was also significant evidence of heterogeneity (Q = 30.31 on 15 d.f., P = 0.011; and I² = 50.5%, P = 0.011). To reduce the influence of publication bias, we used the trim and fill method for both adjusted and unadjusted estimates. This method added five estimates to balance the funnel plot (supplemental Fig. B), and the adjusted risk estimate was attenuated but remained significant (OR 1.52 [1.13–2.04]).

five studies reported the risk of diabetes on postoperative mortality in patients undergoing treatment for cancer of the esophagus or gastroesophageal junction (15–19). Karl et al. (17) and Abu-nasra et al. (18) reported rates of 30-day mortality in colorectal cancer patients with and without diabetes from the Veteran’s Affairs Database. After adjustment for confounders, they observed a significant increase in risk for patients with diabetes (HR 1.19 [95% CI 1.04–1.36]).

Five studies reported the risk of diabetes on postoperative mortality in patients undergoing treatment for cancer of the esophagus or gastroesophageal junction (15–19). Karl et al. (17) and Abu-nasra et al. (18) reported rates of 30-day mortality in colorectal cancer patients with and without diabetes from the Veteran’s Affairs Database. After adjustment for confounders, they observed a significant increase in risk for patients with diabetes (HR 1.19 [95% CI 1.04–1.36]).

Figure 1—Flowchart of study selection.
Analysis of influence for the overall pooled estimate revealed that the risk of postoperative mortality among patients with diabetes remained significant with the omission of each study in turn (data not shown). When the analysis of influence was repeated in the five studies that reported adjusted estimates, the pooled risk estimate ranged from OR 1.32 (95% CI 1.10–1.59) to 1.73 (1.23–2.43) and remained statistically significant with the omission of each study.

CONCLUSIONS — We found that preexisting diabetes conferred a 50% increased risk of mortality in newly diagnosed cancer patients after surgery. This additional risk was present across a range of cancers and a range of surgical cancer treatments. It was not explained by confounding factors, publication bias, or undue influence by a single study. Strengths of our study include a comprehensive systematic review of the literature by a multidisciplinary team including specialists in cancer, diabetes, and epidemiologic methods. We used a broad search strategy to capture all relevant information.

Limitations of the literature and of our systematic review and meta-analysis deserve comment. First, the published literature showed great heterogeneity in population demographics and in assessment of confounders. Despite the use of appropriate meta-analytic techniques with random-effect models, we were unable to account fully for these differences. However, we continued to observe a significant association when limiting our pooled estimate to adjusted models, most of which were high-quality studies performed in large cohorts. Second, we found no studies evaluating the effect of diabetes on postoperative mortality in women with breast or endometrial cancer. Thus, we are uncertain whether our findings apply to women with these cancers.

All articles included in the present systematic review were based on surgical cohorts. A notable gap in the literature is data regarding diabetes’ effect on short-term survival in cancer patients who do not undergo surgery. This gap may be especially important because diabetes is known to influence treatment decisions and might steer some patients toward nonsurgical treatment (2).

Previous studies of preexisting diabetes and the risk of postoperative or in-hospital mortality related to noncancer surgery have shown mixed results (30,31). However, there are two main pathways through which preexisting diabetes might specifically influence postoperative mortality risk after cancer surgery. The first pathway is via sepsis and other serious infection. Diabetes is a well-established risk factor for infection and for infection-related mortality in the general population. Diabetes complications like peripheral arterial disease and bladder dysfunction represent chronic predisposing factors. In addition to these factors is perioperative hyperglycemia, which predicts in-hospital infection likely re-
Cancer patients with preexisting diabetes

lated to acute effects on leukocyte function (32). In a population of bone marrow transplantation recipients, who are highly susceptible to infection, Derr et al. (33) reported positive associations between preneutropenia glycaemia and risks of any infection and bloodstream infection.

The second pathway to postoperative mortality risk is via myocardial infarction. Diabetes is a chronic risk factor for atherosclerosis in multiple vascular beds, including the coronary arteries, and is a strong predictor of myocardial infarction and cardiovascular disease death in the general population (34). Superimposed on long-standing atherosclerosis are short-term effects of hyperglycaemia on platelet function and thrombotic tendency (35). Perioperative renal failure (e.g., diabetes-related contrast nephropathy), in addition to diabetes-related chronic kidney disease (36), may also aggravate cardiovascular risk.

These observations raise a therapeutic question: might improvements in perioperative diabetes care reduce the risk of postoperative mortality after cancer surgery? There are no clinical trials that address this question directly. Trials and quasi-experimental studies of improved glycemic control in the setting of non-cancer surgery have been generally favorable (37,38). However, randomized controlled trials of intensive insulin therapy to achieve glycemic control in surgical intensive care units have yielded mixed results (39,40).

The main implication of our study is that oncologists, surgeons, and cancer patients should be aware of the excess postoperative mortality risk related to diabetes when considering treatment options. Whether improvements in perioperative diabetes care can reduce this excess risk is uncertain. Future research should investigate physiologic pathways to mortality risk and determine whether improvements in perioperative diabetes care can reduce postoperative mortality.

Acknowledgments—B.B.B. and R.L.D. were supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Diabetes and Obesity Training Grant (T32 DK062707). C.F.S. was supported by an American Cancer Society Mentored Research Scholar Grant (MRSG-08-011-01-CPPB). K.B.S. was supported by a National Institutes of Health fellowship from Health Services and Administration (T32HP10025-14). F.L.B. was supported by the NIDDK Patient Oriented Research in Type 2 Diabetes Grant (K24-DK62222). H.-C.Y. and F.L.B. were supported by the NIDDK Diabetes Research and Training Center (P60 DK079637).

No potential conflicts of interest relevant to this article were reported.

Parts of this study were presented at the 69th Scientific Sessions of the American Diabetes Association, New Orleans, Louisiana, 5–9 June 2009.

References

1. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047–1053
2. Richardson LC, Pollack LA. Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer. Nat Clin Pract Oncol 2005;2:48–53
3. Ko C, Chaudhry S. The need for a multidisciplinary approach to cancer care. J Surg Res 2002;105:53–57
4. Barone BB, Yeh HC, Snyder CF, Pears KS, Stein KB, Derr RL, Wolf LC, Brancati FL. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 2008;300:2754–2764
5. Inzucchi SE. Clinical practice: management of hyperglycemia in the hospital setting. N Engl J Med 2006;355:1903–1911
6. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening of Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology 2007;18:800–804
7. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–560
8. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177–188
9. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000;56:455–463
10. Koperna T, Kiss M, Schulz F. Emergency surgery for colon cancer in the aged. Arch Surg 1997;132:1032–1037
11. Little SA, Jarnigan WR, DeMatteo RP, Blumgart LH, Fong Y. Diabetes is associated with increased perioperative mortality but equivalent long-term outcome after hepatic resection for colorectal cancer. J Gastrointest Surg 2002;6:88–94
12. Tsugawa K, Koyanagi N, Hashizume M, Akahoshi K, Wada H, Ayukawa K, Tomikawa M, Sugimachi K. Therapeutic strategy of emergency surgery for colon cancer in 71 patients over 70 years of age in Japan. Hepatogastroenterology 2002;49:393–398
13. Davila JA, Rabeneck L, Berger DH, El-Serag HB. Postoperative 30-day mortality following surgical resection for colorectal cancer in veterans: changes in the right direction. Dig Dis Sci 2005;50:1722–1728
14. Jullumstre A, Kollind M, Lydersen S, Edna TH. Diabetes mellitus and outcomes of colorectal cancer. Acta Oncologica 2009;48:361–367
15. Zhang GH, Fujita H, Yamana H, Kakegawa T. A prediction of hospital mortality after surgical treatment for esophageal cancer. Surg Today 1994;24:122–127
16. Barrie H, Stein HJ, Siewert JR. Preoperative risk analysis and postoperative mortality of oesophagectomy for resectable oesophageal cancer. Br J Surg 1998;85:840–844
17. Karl RC, Schreiber R, Boulware D, Baker S, Coppola D. Factors affecting morbidity, mortality, and survival in patients undergoing Ivor Lewis esophageagastrectomy. Ann Surg 2000;231:635–643
18. Abunasra H, Lewis S, Beggs D, Morgan E. Predictors of operative death after oesophagectomy for carcinoma. Br J Surg 2005;92:1029–1033
19. Wright CD, Kucharczuk JC, O’Brien SM, Grab JD, Allen MS, Society of Thoracic Surgeons General Thoracic Surgery Database. Predictors of major morbidity and mortality after esophageal cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database risk adjustment model. J Thorac Cardiovasc Surg 2009;137:587–596
20. Nagasue N, Kohno H, Chang YC, Taniura H, Yamanoi A, Uchida M, Kimoto T, Takemoto Y, Nakamura T, Yukaya H. Liver resection for hepatocellular carcinoma: results of 229 consecutive patients during 11 years. Ann Surg 1993;217:375–384
21. Poon RT, Fan ST, Wong J. Does diabetes mellitus influence the perioperative outcome or long term prognosis after resection of hepatocellular carcinoma? Am J Gastroenterol 2002;97:1480–1488
22. Romano PS, Mark DH. Patient and hospital characteristics related to in-hospital mortality after lung cancer resection. Chest 1992;101:1332–1337
23. Au J, el-Oakley R, Cameron EW. Pneumonectomy for bronchogenic carcinoma in the elderly. Eur J Cardiothorac Surg 1994;8:247–250
24. Duque JL, Ramos G, Castredoza J, Cerejal J, Castanedo M, Yuste MG, Heras F. Early complications in surgical treatment of lung cancer: a prospective, multicenter study. Grupo Cooperativo de Carcinoma Broncogénico de la Sociedad Española de Neumología y Cirugía Torácica. Ann Thorac Surg 1997;63:944–950
25. Dominguez-Ventura A, Allen MS, Cassivi SD, Nichols FC 3rd, Deschamps C, Pia- roloro PC. Lung cancer in octogenarians.
factors affecting morbidity and mortality after pulmonary resection. Ann Thorac Surg 2006;82:1175–1179
26. Wu CW, Hsieh MC, Lo SS, Wang LS, Hsu WH, Lui WY, Huang MH, Peng FK. Morbidity and mortality after radical gastrectomy for patients with carcinoma of the stomach. J Am Coll Surg 1995;181:26–32
27. Andrén-Sandberg A, Ihse I. Factors influencing survival after total pancreatectomy in patients with pancreatic cancer. Ann Surg 1983;198:605–610
28. Bakkevold KE, Kambestad B. Morbidity and mortality after radical and palliative pancreatic cancer surgery. Risk factors influencing the short-term results. Ann Surg 1993;217:356–368
29. Wilt TJ, Cowper DC, Gammack JK, Going DR, Nugent S, Borowsky SJ. An evaluation of radical prostatectomy at Veterans Affairs Medical Centers: time trends and geographic variation in utilization and outcomes. Med Care 1999;37:1046–1056
30. Rajakaruna C, Rogers CA, Suranimala C, Angelini GD, Ascione R. The effect of diabetes mellitus on patients undergoing coronary surgery: a risk-adjusted analysis. J Thorac Cardiovasc Surg 2006;132:802–810
31. Filsoufi F, Rahmanian PB, Castillo JG, Mechanick JI, Sharma SK, Adams DH. Diabetes is not a risk factor for hospital mortality following contemporary coronary artery bypass grafting. Interact Cardiovasc Thorac Surg 2007;6:753–758
32. Golden SH, Peart-Vigilance C, Kao WH, Brancati FL. Perioperative glycemic control and the risk of infectious complications in a cohort of adults with diabetes. Diabetes Care 1999;22:1408–1414
33. Derr RL, Hsiao VC, Saudek CD. Antecedent hyperglycemia is associated with an increased risk of neutropenic infections during bone marrow transplantation. Diabetes Care 2008;31:1972–1977
34. Saydah SH, Eberhardt MS, Loria CM, Brancati FL. Age and the burden of death attributable to diabetes in the United States. Am J Epidemiol 2002;156:714–719
35. Grant PJ. Diabetes mellitus as a prothrombotic condition. J Intern Med 2007;262:157–172
36. Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers J, Farid N, McManamon PJ. Contrast material-induced renal failure in patients with diabetes mellitus, renal insufficiency, or both: a prospective controlled study. N Engl J Med 1989;320:143–149
37. Ramos M, Khalpey Z, Lipsitz S, Steinberg J, Panizales MT, Zinner M, Rogers SO. Relationship of perioperative hyperglycemia and postoperative infections in patients who undergo general and vascular surgery. Ann Surg 2008;248:585–591
38. McAlister FA, Man J, Bistritz L, Amad H, Tandon P. Diabetes and coronary artery bypass surgery: an examination of perioperative glycemic control and outcomes. Diabetes Care 2003;26:1518–1524
39. van den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345:1359–1367
40. Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. JAMA 2008;300:933–944